Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
SAN RAFAEL, Calif., Jan. 28, 2016 -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 25, at 4:30 p.m. ET to discuss fourth quarter and full year 2015 financial results and provide a general business update.
Dial-in Number
U.S. / Canada Dial-in Number: (877) 303-6313
International Dial-in Number: (631) 813-4734
Conference ID: 34535772
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 34535772
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com.
Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451
